Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
25.00
+5.36 (27.29%)
NASDAQ · Last Trade: Oct 28th, 4:14 PM EDT
Detailed Quote
Previous Close
19.64
Open
22.50
Bid
24.99
Ask
25.01
Day's Range
22.00 - 25.75
52 Week Range
8.210 - 21.84
Volume
11,488,675
Market Cap
1.26B
PE Ratio (TTM)
-33.78
EPS (TTM)
-0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,995,360
Chart
About Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Arcutis Biotherapeutics Inc is a biopharmaceutical company focused on developing innovative treatments for dermatological conditions. The company is dedicated to addressing unmet medical needs by leveraging its expertise in immunology and dermatology to create topical therapies that enhance the quality of life for patients suffering from skin disorders. Through its research and development efforts, Arcutis aims to deliver effective and safe solutions for common conditions such as psoriasis, eczema, and other inflammatory skin diseases, emphasizing patient-centric approach and scientific rigor in its product development pipeline. Read More
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
Arcutis (ARQT) Q3 2025 earnings crush estimates with a surprise profit. Revenue of $99.2M beats forecasts, driving the stock up 16% on strong ZORYVE demand.
WESTLAKE VILLAGE, Calif. and LAS VEGAS, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that new data demonstrating ZORYVE® (roflumilast) cream 0.15% and 0.05% improved quality of life, specifically by helping to reduce sleep disruptions, and provided long-term, durable disease control for individuals with atopic dermatitis aged 2 years and older will be presented at the 2025 Fall Clinical Dermatology Conference, taking place October 23–26, 2025, in Las Vegas.
WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age. Once-daily ZORYVE cream 0.05% provides rapid and significant clearance of atopic dermatitis anywhere on the body and offers clinicians, parents, and caregivers of children ages 2 to 5 an alternative to steroids that can be used for any duration.
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET.
WESTLAKE VILLAGE, Calif. and PARIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that new data on ZORYVE (roflumilast) efficacy across three common skin conditions—seborrheic dermatitis, atopic dermatitis, and psoriasis—will be presented at the 34th Annual European Academy of Dermatology and Venereology (EADV) Congress, which is taking place September 17–20, 2025, in Paris.
WESTLAKE VILLAGE, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE was presented with a 2025 Best of Beauty Breakthrough Award by Allure magazine, which is globally recognized as the most distinguished beauty award by industry professionals and consumers. ZORYVE is the first prescription topical medication for eczema, plaque psoriasis, and seborrheic dermatitis to win the prestigious Allure Best of Beauty Breakthrough Award, which highlights groundbreaking innovations transforming the skincare category.
Discover ARQT stock, a top growth pick blending Minervini's strong trend template with explosive earnings and sales momentum for potential outperformance.
WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2. If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor treatment indicated for plaque psoriasis in children down to age 2.
Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies
Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors.
